以岭药业:2024年报净利润-7.25亿 同比下降153.62%

Financial Performance - The company reported a basic earnings per share of -0.4337 yuan for 2024, a decrease of 153.58% compared to 0.8095 yuan in 2023 [1] - Net profit for 2024 was -7.25 billion yuan, down 153.62% from 13.52 billion yuan in 2023 [1] - Operating revenue decreased by 36.88% to 65.13 billion yuan in 2024 from 103.18 billion yuan in 2023 [1] - The return on equity (ROE) fell to -6.69% in 2024 from 12.16% in 2023, a decline of 155.02% [1] - The net asset per share decreased by 10.66% to 6.12 yuan in 2024 from 6.85 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 71,312.99 million shares, accounting for 51.8% of the circulating shares, a decrease of 2,228.21 million shares from the previous period [2] - Yiling Pharmaceutical Technology Co., Ltd. remains the largest shareholder with 52,677.60 million shares, representing 38.26% of total share capital, unchanged from the previous report [3] - Hong Kong Central Clearing Limited reduced its holdings by 295.70 million shares, now holding 2,865.40 million shares, which is 2.08% of total share capital [3] - New entrants to the top ten shareholders include Southern CSI 500 ETF with 1,185.92 million shares (0.86%) and Wu Xizhen with 508.57 million shares (0.37%) [3]